Corrigendum to ‘‘An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension” [Regul. Toxicol. Pharmacol. 2012, 95–103]

✍ Scribed by Owen, Keith; Cross, David M.; Derzi, Mazin; Horsley, Elizabeth; Stavros, Fiona L.

• Book ID: 118507400
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 120 KB
• Volume: 64
• Category: Article
• ISSN: 0273-2300
• DOI: 10.1016/j.yrtph.2012.07.012